ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0276

Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy

Raeann Whitney1, Amanda Eudy2, Cynthia Coffman3, Megan Clowse4, Lisa Criscione-Schreiber5, Jayanth Doss2, Rebecca Sadun2, Kai Sun2 and Jennifer Rogers6, 1Duke University Medical Center, Durham, NC, 2Duke University, Durham, NC, 3Duke University, Durham, 4Duke University, Chapel Hill, NC, 5Duke University School of Medicine, Durham, NC, 6Duke, Durham, NC

Meeting: ACR Convergence 2020

Keywords: Fatigue, fibromyalgia, Patient reported outcomes, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Friday, November 6, 2020

Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Management of Type 2 SLE (widespread pain, fatigue, depression, sleep distrubance, and cognitive dysfunction) is challenging and often requires multiple medications to ameliorate symptoms. Polypharmacy can increase the risk of drug interactions, side effects, adverse reactions, non-adherence, and lead to greater healthcare costs. Many medications used for Type 2 SLE are associated with QTc interval prolongation. The purpose of this study was to examine symptoms and Type 2 medication polypharmacy.

Methods: This was a cross-sectional study of SLE patients (SLICC 2012 criteria) enrolled in a university registry from May 2018-March 2019. All patients completed the Systemic Lupus Activity Questionnaire (SLAQ), Patient Health Questionnaire-9 (PHQ-9), and 2016 ACR Fibromyalgia criteria questionnaires. Type 2 SLE was defined as a polysymptomatic distress (PSD) score ≥8. Type 2 medications included antidepressants (serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), mirtazapine, bupropion, muscle relaxers (cyclobenzaprine, baclofen, metaxalone), gabapentinoids (gabapentin, pregabalin), topiramate, zolpidem, trazodone, tramadol, anxiolytics, stimulants, and DHEA. Relationships between clinical variables and medications in different groups were analyzed using ANOVA and Fisher’s exact test.

Results: One hundred and fifty-nine patients completed surveys (96% female, 66% Black, 42% Type 2 SLE.) Type 2 medications were prescribed in 50% of patients. Patients on Type 2 medications were older and had longer duration of SLE (Table 1). Multiple Type 2 medication use was more frequent in Type 2 SLE patients than non-Type 2 patients (43% vs 25.7%). The average number of Type 2 medications was 1.9. Of patients taking Type 2 medications, 72% were taking at least one QTc interval prolonging Type 2 medications (mean 1.3 medications).

Despite pharmacologic therapy, 58% of SLE patients had active Type 2 SLE (Table 2). The number of patients with depression and Type 2 SLE activity was greater in those on multiple medications. Moreover, the severity of nearly all Type 2 SLE symptoms including widespread pain, fatigue, depression, forgetfulness and sleep dysfunction was greatest in those on more than one Type 2 medication compared to no Type 2 medications or one Type 2 medication.

Conclusion: SLE patients have distressing Type 2 symptoms that often require complex pharmacologic interventions. Although the majority of patients with Type 2 SLE activity take therapies aimed at these symptoms, they continue to have a multitude of symptoms. Furthermore, severe symptoms persist despite nearly half of patients taking multiple medications. Several Type 2 medications can prolong the QTc interval, which when combined with other QTc prolonging medications such as hydroxychloroquine, can augment the risk of arrhythmia. The average number of Type 2 SLE medications is similar to the number used for Type 1 SLE, highlighting the difficulty managing Type 2 SLE, the need for targeted Type 2 therapeutics, and the importance of non-pharmacologic management.

Table 1. Characteristics of SLE patients by Type 2 medication use

Table 2. Type 2 SLE symptoms and Type 2 medication polypharmacy


Disclosure: R. Whitney, None; A. Eudy, NIH NCATS Award Number 1KL2TR002554, 2, Pfizer, 2; C. Coffman, None; M. Clowse, UCB, 5, GSK, 2, 5, Astra Zeneca, 5, Pfizer, 2; L. Criscione-Schreiber, None; J. Doss, None; R. Sadun, None; K. Sun, None; J. Rogers, None.

To cite this abstract in AMA style:

Whitney R, Eudy A, Coffman C, Clowse M, Criscione-Schreiber L, Doss J, Sadun R, Sun K, Rogers J. Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/type-2-sle-symptoms-persist-despite-type-2-medication-polypharmacy/. Accessed January 27, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/type-2-sle-symptoms-persist-despite-type-2-medication-polypharmacy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.